|
||
Article |
Address correspondence to Jorma Keski-Oja, Department of Pathology, P.O. Box 63, Biomedicum Helsinki, University of Helsinki, Helsinki FIN-00014, Finland. Tel.: 358-9-191-25566. Fax: 358-9-191-25573. email: jorma.keski-oja{at}helsinki.fi
| Abstract |
|---|
|
|
|---|
Key Words: extracellular matrix; LTBP; cell adhesion; antiadhesion; fibronectin
| Introduction |
|---|
|
|
|---|
Fibrillins were first identified as components of elastic tissue microfibrils. Microfibrils consist, in addition to fibrillins, of several other proteins like microfibril-associated glycoproteins (MAGPs) 1 and 2 (Rosenbloom et al., 1993). Fibrillins are important for the structure of microfibrils, as shown by mice expressing mutated fibrillin-1 forms (Pereira et al., 1997; Kielty et al., 1998; Gayraud et al., 2000). TGF-ßs are secreted from cells as latent complexes composed of the mature dimeric growth factor together with its NH2-terminal latency-associated peptide (Saharinen et al., 1999; Annes et al., 2003). The secretion of small latent (SL) TGF-ß from the cells is augmented by LTBP-1 (Miyazono et al., 1991), and LTBP-1 directs this complex to the ECM (Taipale et al., 1994). At least LTBP-1 has a role in the activation of latent TGF-ß (Flaumenhaft et al., 1993). LTBP-1 localizes to the fibrillin-containing ECM microfibrils as well as to the pericellular cell surfaceassociated fibronectin (FN) fibrils (Taipale et al., 1996; Isogai et al., 2003). The majority of LTBP-1 protein is secreted from the cells without SL-TGF-ß (Taipale et al., 1994), suggesting that LTBP-1 has novel functions, like structural roles in the ECM.
After the identification of LTBP-1 (Kanzaki et al., 1990), three other LTBPs have been cloned, namely LTBP-2, -3, and -4 (Moren et al., 1994; Yin et al., 1995; Giltay et al., 1997; Saharinen et al., 1998). LTBP-2 has been localized by immunoelectron microscopy to the elastic microfibrils in bovine tissues (Gibson et al., 1995). While LTBP-1, -3, and -4 are true SL-TGF-ß binding proteins, LTBP-2 is unable to bind SL-TGF-ß (Saharinen and Keski-Oja, 2000). In addition, gene-targeted mice for LTBP-2 show early embryonic lethality (Shipley et al., 2000) differing from the phenotypes of all TGF-ß (TGF-ß1, -ß2, and -ß3) gene knockout mice (Shull et al., 1992; Proetzel et al., 1995; Sanford et al., 1997). This indicates that at least LTBP-2 has important functions not related to TGF-ß.
Cell interactions with ECM components are a central, regulated cascade of events both during embryo- and organogenesis and during later stages of life (Gumbiner, 1996). Cells adhere to the ECM via cell surface receptors, often via integrin receptors and RGD recognition sequences of ECM proteins (Ruoslahti, 1996). FN (Vaheri and Ruoslahti, 1975) is the most widely studied example of an adhesive ECM component. Earlier studies indicated that LTBP-2associated ECM components, such as fibrillin-1 and MAGP-2, mediate cell adhesion, at least in part via their RGD sequences (Sakamoto et al., 1996; Gibson et al., 1999). LTBP-2 contains an RGD cell adhesion sequence, which led us to explore the possible adhesive functions of LTBP-2 for human lung fibroblasts. We chose lung fibroblasts for our studies because lung is the major site of LTBP-2 expression (Moren et al., 1994). These cells attached to a specific proline-rich NH2-terminal fragment of LTBP-2, which did not, however, contain the RGD sequence. Fibroblasts adhering to this fragment did not spread appreciably or form actin stress fibers. In contrast, this fragment exhibited a dominant cytoskeleton formationdisrupting effect on fibroblasts. LTBP-2 and especially its proline-rich NH2-terminal region exerted modulatory effects on the actin cytoskeleton of fibroblasts and induced a less adherent phenotype. LTBP-2 is thus a new member to the family of extracellular antiadhesive glycoproteins.
| Results |
|---|
|
|
|---|
|
80 kD, but it migrated as an almost 200-kD band. The reason for its aberrant migration in SDS-PAGE is unclear at present.
The histidine-tagged LTBP-2 fragments were purified by metal chelate chromatography as described above. In addition to the fragments, there was occasionally an
65-kD contaminating protein, which copurified from CHO-conditioned medium in metal chelate chromatography (Fig. 1 B, lane L2-N*). It could be removed with gel filtration and was not responsible for the cell adhesion effects of the LTBP-2 fragments (not depicted).
Lung fibroblasts bind to an NH2-terminal fragment of LTBP-2
As LTBP-2 has a potential cell adhesionmediating RGD sequence (Fig. 1 A) (Ruoslahti, 1996), we analyzed first the properties of LTBP-2 and its recombinant fragments in cell adhesion assays (Fig. 2 A) using FN as a control. Full-length LTBP-2 did not display significant effects in the cell binding assays with any of the coating concentrations used (Fig. 2 A and not depicted). Unexpectedly, fibroblasts adhered to fragment L2-IV, which contains the hybrid domain and the preceding proline-rich area (illustrated in Fig. 1). The number of cells attaching to wells coated with this fragment was constantly lower than that attached to FN-coated wells (maximally
60% of the binding to FN).
|
To confirm the results and to rule out the possibility that the adherence would be caused by artificial dimer formation of Ig fusion proteins, we expressed, purified, and repeated the adhesion assays with histidine-tagged fragments of LTBP-2 (Fig. 3). Two NH2-terminal fragments were produced, a larger one, covering most of the NH2-terminal half of LTBP-2 (L2-N*), and a short one (L2-V*), corresponding to fragment L2-V. As expected, lung fibroblasts adhered to both fragments in a concentration-dependent manner. The fragments exhibited bell-shaped doseresponse effects: after reaching a critical coating concentration, cell adhesion decreased.
|
|
|
10% decrease) on the number of cells adhering to FN substratum (Fig. 5 A), and statistical values were P > 0.05, when cell adhesion was compared with cells adhering to FN. As LTBP-2 proved later to have antiadhesive effects (see next paragraph), we compared its effects to tenascin-C, a known antiadhesive protein (Chiquet-Ehrismann et al., 1988; Huang et al., 2001). The effects of tenascin-C were of the same magnitude as those of LTBP-2. Next, we investigated the effects of LTBP-2 on actin cytoskeletons of cells attaching to FN. Full-length LTBP-2 and its NH2-terminal fragments had a dominant actin stress fiber formationdisrupting effect on fibroblasts when compared with cells plated on FN alone (Fig. 5 B). Actin staining was mainly localized to the cell periphery, including membrane ruffles and patch-like structures at the extremities of the cells, resembling very much the cells plated on LTBP-2 fragments only (compare with Fig. 4), whereas cells plated on FN formed extensive stress fibers. The effect resembled that of tenascin-C. In addition, cells cultured on LTBP-2/FN substratum were less spread than control cells (Fig. 6 A). The COOH-terminal control fragment L3-C* derived from LTBP-3 (Penttinen et al., 2002) did not exhibit any detectable effects on cell morphology or actin cytoskeleton formation (Fig. 5 B).
|
Antiadhesive effect of LTBP-2 is concentration dependent
We explored next the concentration dependency of the antiadhesive effect of LTBP-2. Glass coverslips were coated with a constant concentration of FN, and subsequently with increasing concentrations of LTBP-2 or fragment L2-N* or L2-V*. The cells were stained for actin 90 min after plating. Cells were then observed in fluorescence microscopy and the cell spreading was quantified. Low concentrations of LTBP-2 (1.25 µg/ml) had only minor effects (Fig. 6 A). With increasing concentrations of LTBP-2, cell spreading decreased steadily (Fig. 6 A, the lowermost panel), as well as the number of cells forming stress fibers (Fig. 6 B). With the highest LTBP-2 concentration used (20 µg/ml), the cells did not form any stress fibers and spread even less than cells on BSA-coated substratum. These effects were similar to those obtained by using tenascin-C (Fig. 6 B and not depicted). The fragments L2-N* and L2-V* had quite similar concentration-dependent effects on cell morphology and actin cytoskeleton organization. However, the actin cytoskeleton and cell spreadingdisrupting effects were less efficient than with full-length LTBP-2 (Fig. 6 A). Unlike LTBP-2 itself, the fragments reached a saturating concentration. The increase of the coating concentration over a certain limit (2.5 µg/ml with L2-N* and 1.25 µg/ml with L2-V*) did not further inhibit cell spreading or prevent further actin cytoskeleton organization (compare with LTBP-2 panel).
LTBP-2 and its antiadhesive fragments bind to FN
To gain an insight into the mechanisms of the antiadhesive property, we analyzed whether LTBP-2 or its antiadhesive fragments could bind directly to FN or collagen type I. For this purpose, we established an enzyme-linked immunosorbent assay. Plates of 96 wells were first coated with increasing concentrations of FN or collagen type I. Both proteins coated the plates effectively under these conditions. Soluble LTBP-2 or its fragments were then incubated in the wells in a buffer containing BSA to prevent binding of LTBP-2 to BSA. Bound LTBP-2 was detected with polyclonal affinity-purified antibodies, and histidine-tagged fragments were detected with monoclonal antibody recognizing the histidine tag (Fig. 7 A). We observed that LTBP-2 and its fragments L2-V* and L2-N* bound to FN in a concentration-dependent and saturable manner, showing the specificity of binding (Fig. 7). In contrast, no binding of LTBP-2 to collagen type I was observed.
|
|
The antiadhesive fragment L2-V* localized to the extracellular/pericellular matrix as well (Fig. 8, L2-V*). The staining was more discontinuous than that of fragment L2-N*. The staining clearly colocalized with FN in many, but not all, locations.
Histidine-tagged fragment L2-X* was used as a control. This fragment was detected at the surfaces of the cells (Fig. 8, L2-X*), and no obvious colocalization with FN was detected.
COS-7 cells form relatively sparse extracellular matrices. We have therefore repeated the assays using human lung fibroblasts. The results were similar (unpublished data), but the transfection efficiencies of fibroblasts were very poor, which prevented their use in the assays.
LTBP-2 is not antiadhesive for cells adhering to type I collagen
We determined next whether the actin cytoskeletondisrupting effect of LTBP-2 would be specific for FN. For this purpose, we coated coverslips with FN or collagen type I. Fibroblasts adhered more avidly to collagen type I than FN (unpublished data), permitting the use of lower concentrations of it (Fig. 9). After saturation of nonspecific binding sites with BSA, the coverslips were incubated with LTBP-2. Under these conditions, LTBP-2 bound to both types of coverslips, coated either with FN or collagen type I (not depicted). Cells adhered and formed stress fibers efficiently on coverslips coated either with FN or collagen type I (Fig. 9). However, in the presence of LTBP-2, the cells adhering to FN were clearly less adherent and more rounded, whereas LTBP-2 had no appreciable effects on cells adhering to collagen type I (Fig. 9). We analyzed a wide range of FN and collagen type I coating concentrations in the assays. The effects of LTBP-2 on cells adhering to FN were always prominent, whereas effects on cells adhering to collagen type I were negligible (unpublished data). These results indicated that even though LTBP-2 is present on coverslips coated with both FN and collagen type I, the cytoskeleton-disrupting effect of LTBP-2 is effective only for cells adhering to FN.
|
| Discussion |
|---|
|
|
|---|
Fibrillins and other microfibril components, MAGP-2 (Gibson et al., 1999; Bax et al., 2003), mediate cell adhesion via RGD sequences. Fibrillin-1 seems to mediate cell adhesion also via non-RGDdependent ways (Sakamoto et al., 1996). LTBP-2 possesses a putative cell adhesionmediating RGD sequence, which led us to examine the effects of LTBP-2, and especially its NH2 terminus, on cell adhesion.
Although full-length LTBP-2 did not mediate cell adhesion, we found with Ig-tagged fragments an area that supported fibroblast binding in cell adhesion assays. This activity was localized to the NH2 terminus of LTBP-2 at the variable region toward the COOH terminus from the second EGF-like repeat and toward the NH2 terminus from the hybrid domain. This region is rich in proline and positively charged amino acids and has no defined domain properties. The RGD sequence is not located at this area. When reanalyzing the results with histidine-tagged fragments, we observed that cell adhesion to plates coated with recombinant fragments of this region did not induce actin stress fiber formation, even though the cells spread slightly more efficiently than cells attaching onto BSA-coated coverslips. Actin was localized in these cells to membrane ruffles. In addition, we found that this region of LTBP-2 exhibited a concentration-dependent, bell-shaped effect on cell adhesion. This suggested that LTBP-2 might have antiadhesive properties and guided us to explore possible combinatory effects of LTBP-2 and the adhesive ECM components FN and type I collagen on cell adhesion and morphology.
We found that full-length LTBP-2, its NH2-terminal half, and the proline-rich region (fragment L2-V) had dramatic and dominant effects on the morphology of cells adhering to FN. Both LTBP-2 and its NH2-terminal fragments prevented stress fiber formation and caused actin redistribution to the cell periphery. Cell spreading was also slightly impaired, and the cells were more rounded, contributing to a less adherent morphology. Accordingly, LTBP-2 disrupted focal adhesion formation. Paxillin and vinculin, proteins localizing normally to focal adhesions in adherent cells, localized mostly to patchy structures in the cytoplasm and partially to membrane ruffles in the presence of LTBP-2. Although the effect of LTBP-2 on the number of attaching cells was minor, the cytoskeletal changes were comparable to the other antiadhesive proteins such as SPARC (Sage et al., 1989) and thrombospondin (Murphy-Ullrich and Höök, 1989). This justifies the usage of the term antiadhesive with LTBP-2.
The effect was characteristic of FN; cells adhering to type I collagen exhibited normal cell morphology and actin cytoskeletons in the presence of LTBP-2. The tested proteins comprise only a small number of adhesive ECM components, and it will be of interest to analyze whether the antiadhesive effect of LTBP-2 is specific for example for certain integrins.
To obtain mechanistic insights for the antiadhesive effect of LTBP-2, we established a binding assay for LTBP-2. We noted that LTBP-2 binds to FN in a specific, saturable manner but not to type I collagen. In addition, in binding experiments with histidine-tagged fragments, we found that the fragments with antiadhesive properties bound to FN as well. Interestingly, the same fragments associated with the ECM and colocalized with FN in cell cultures.
In contrast to NH2-terminal fragments, full-length LTBP-2 had no effects on cell adhesion, when coated separately. This fact suggests that the cell adhesive function is cryptic in full-length LTBP-2. However, FN-bound full-length LTBP-2 had antiadhesive effects on fibroblasts. We therefore propose that the binding of LTBP-2 to FN may result in exposure of cryptic, antiadhesive regions of LTBP-2.
We performed assays where we studied the concentration dependency of the antiadhesive effect of LTBP-2 and its fragments. Full-length LTBP-2 was the most effective in mediating antiadhesion, and the effects became more prominent when increasing the concentration of LTBP-2. In contrast, the fragments of LTBP-2 reached a saturation point. When increasing the coating concentration above a critical point, the effect was saturated. The maximal effects were not as drastic as with full-length LTBP-2. This effect may result from the saturation of LTBP-2 fragment binding sites in FN. LTBP-2 fragments may act by binding to FN (compare Figs. 6 and 7) and blocking some adhesive epitopes in FN. Full-length LTBP-2 may contain some additional binding sites/mechanisms for antiadhesion.
The above-mentioned observations suggest that LTBP-2 has an ability to bind to FN localized to ECM and mask its adhesive epitopes. Tenascin-C, a related antiadhesive ECM component, has been proposed to exert its effects via this mechanism. Tenascin-C binds FN and prevents syndecan-4 binding to it, causing a less adhesive phenotype in cells (Huang et al., 2001). Interestingly, the effects of tenascin-C were very similar to those of LTBP-2 in our studies. Major antiadhesive effects were observed as decreased stress fiber formation as well as cell spreading. Its effects on the number of attaching cells were minor. In studies by others (Huang et al., 2001) tenascin-C decreased the number of cells attaching to mixed tenascin-C/FN substratum. The noted difference possibly results from different experimental settings, such as the number of cells used in assays.
Fibroblasts were observed to bind to the antiadhesive fragment of LTBP-2. The morphology of the cells attaching to the fragments was strikingly similar to cells attaching to FN/LTBP-2 substratum. This suggests that the cell-binding activity is related to its antiadhesive effect. Furthermore, the fact that cells bind to the antiadhesive fragment suggests that there might be a cell surface receptor recognizing this region of LTBP-2. This hypothetical cell surface component could act either in integrin adhesion complexes by sterically hindering integrin binding to its ligand, or alternatively as separate signaling receptors, affecting signal transduction and preventing integrin activation and cell adhesion. This kind of mechanism has been proposed for thrombospondin, another antiadhesive ECM protein. The NH2-terminal fragment of thrombospondin binds to calreticulin at the cell surface, which affects the focal adhesion integrity (Goicoechea et al., 2000). However, so far we have not been able to detect such receptors.
We have observed recently that LTBP-2 acts as an adhesion protein for cultured melanoma cells (Vehviläinen et al., 2003). Melanoma cell adhesion leads to efficient cell spreading, and the actin cytoskeletons appeared comparable to cells adhered to FN. The adhesion was at least in part mediated by
3ß1 and, to a lesser extent,
6ß1 integrins. Interestingly, the melanoma cell adhesion site in LTBP-2 was localized to the same proline-rich fragment L2-V, which was antiadhesive for lung fibroblasts in the current study.
FN is a component of the so-called provisional matrices during development and wound healing (Mosher, 1995). We noted LTBP-2 to be antiadhesive of the tested ECM components only for cells adhering to FN. Therefore, it is possible that LTBP-2 has an antiadhesive role only for short periods of time during development when FN exists in ECM fibers. However, the antiadhesive role of LTBP-2 needs to be investigated in regard to the other adhesive ECM components.
Antiadhesion or counteradhesion is a relatively rare, but not extinct, phenomenon among ECM proteins (Chiquet-Ehrismann, 1995). Examples of antiadhesive proteins include thrombospondin, tenascin, and SPARC (BM-40). The modulation of cell adhesion is often related to cell migration. Filopodia and lamellipodia formation is crucial for cell movement, and the actin cytoskeleton plays an important role in these processes (Lauffenburger and Horwitz, 1996). As decreased actin stress fiber formation and increased membrane ruffle formation caused by LTBP-2 and its NH2-terminal fragment L2-V are consistent with the promotion of cell migration, it is tempting to speculate that the antiadhesive property of LTBP-2 is linked to the modulation of fibroblast migration in the lung and other tissues where LTBP-2 is expressed.
| Materials and methods |
|---|
|
|
|---|
Fibroblast adhesion assays
Tissue culture 96-well plates were coated with LTBP-2 or its fragments at the concentrations indicated (50 µl/well) either at 4°C for 16 h, or at 20°C for 1 h in PBS (140 mM NaCl, 10 mM sodium phosphate, pH 7.4). Nonspecific cell adhesion was prevented by incubating the wells with 100 µl of 1% heat-treated (70°C for 1 h) BSA at 22°C for 1 h. The wells were washed with PBS before the adhesion assays.
To detect the effects of LTBP-2 on cells adhering to FN or type I collagen, the tissue culture plates or glass coverslips were first coated with FN (10 µg/ml) or type I collagen (0.33 µg/ml). The proteins were prediluted with PBS at room temperature before coating. Nonspecific binding sites were then saturated with heat-treated BSA as before. Coverslips or plates were then incubated with LTBP-2 (Hyytiäinen et al., 1998; Vehviläinen et al., 2003), its fragments, or recombinant tenascin-C (Fischer et al., 1997) (a gift of R. Chiquet-Ehrismann, Friedrich Miescher Institute, Basel, Switzerland) in PBS containing 1 mM CaCl2, 1 mM MgCl2 for 1 h. The plates were then washed twice with PBS containing 1 mM CaCl2, 1 mM MgCl2.
Cells were detached from plates with trypsin-EDTA and suspended into serum-free MEM. The cells were counted, spun down by centrifugation at 500 g for 5 min, and resuspended in serum-free medium (5 x 105 cells/ml). Aliquots of the cell suspension (100 µl; 5 x 104 cells) were plated in each well. The plates were incubated in a humidified incubator at 37°C for 1 h. Nonattached cells were removed by washing the wells twice with PBS. The cells were then fixed and stained by filtered 0.1% Coomassie blue dissolved in 30% methanol, 10% acetic acid. Subsequently, the cells were washed extensively with 30% methanol/10% acetic acid and once with PBS. The cells were lysed in 1% SDS, and A620 was measured. The results are presented as the mean value obtained from three different wells and compared with the data obtained from cell adhesion to FN. Error bars represent the standard error. Each experiment was performed at least three times.
Expression constructs
LTBP-2 fragments were expressed in stably transfected CHO cells as dimeric NH2-terminal fusion proteins with the Fc portion of immunoglobulin G as follows. Fragments of LTBP-2 cDNA were amplified by PCR using Pfu or Pfu Turbo polymerase (Stratagene) with primers designed to maintain the open reading frame after the signal sequence and to continue to Fc tail in signal pIg+ (R&D Systems) vector. Primer sequences contained HindIII (5' primers, all constructs except L2-X) or BamHI (3' primers, all constructs except L2-VII and L2-VIII) restriction enzyme recognition sites in the 5' end of the primers. Construct L2-VII and L2-VIII 3' primers contained NotI recognition sites, and construct L2-X 5' primer contained KpnI recognition site. L2 constructs contained as a fusion partner amino acids of LTBP-2 as described and illustrated in Fig. 1 A. Amino acid numbering is according to the translated cDNA sequence in Genbank/EMBL/DDBJ (accession no. Z37976). Control protein containing only the constant region of human IgG was obtained by expression of vector pIg+.
Histidine-tagged (six histidines) monomeric fragments were produced using pSecTagA vector (Invitrogen). cDNA fragments were produced by PCR with the primers containing HindIII (5') and NotI (3') restriction enzyme recognition sites. L2-N* contains amino acids 161843, L2-V* amino acids 429550, and L2-X* amino acids 728843 (also illustrated in Fig. 1 A).
PCR fragments were digested with the corresponding restriction enzymes and ligated to vector cut with the same enzymes. In constructs L2-VII and L2-VIII and pSecTag constructs, adenosine nucleotides were first inserted into the 3' ends of the PCR product with Taq polymerase, after which the PCR fragment was cloned into pGEM-T cloning vector (Promega), from which the fragment was cloned to the target vector. All constructs were sequenced to confirm that there were no PCR-derived mutations. Histidine-tagged human LTBP-3 COOH-terminal fragment L3-C* hL3/9111153 was expressed and purified as described previously (Penttinen et al., 2002).
Expression and purification of LTBP-2 fragments
Stable neomycin-resistant CHO cell clones were obtained by transfecting the CHO cells with lipofectamine (Promega) with each expression construct as described earlier (Hyytiäinen et al., 1998). 1 d after transfection, the cells were changed to medium containing 1.5 mg/ml G418 (pIg+) or 0.5 mg/ml zeocin (pSecTag), after which the cells were maintained in the selection medium for 2 wk. Stable drug-resistant cells were dilution cloned to 96-well plates, and the expression of fusion protein was estimated by dot blotting culture medium 12 wk after dilution cloning, using biotinylated protein A (Sigma-Aldrich) or penta-his monoclonal antibody (QIAGEN) as the first conjugate. The IgG fusion proteins were purified from the conditioned medium with protein A affinity chromatography.
Histidine-tagged proteins were first precipitated with 35% (NH4)2SO4. The precipitate was dissolved in the wash buffer (2 M urea, 300 mM NaCl, 50 mM Tris-HCl buffer, pH 7.2). The sample was loaded to Talon metal chelate (CLONTECH Laboratories, Inc.) column. The column was washed with the wash buffer, and the bound proteins were eluted with the same buffer containing 100 mM imidazole. The buffer of the fractions containing the fusion proteins was then exchanged to PBS with Fast Desalting column HR 10/10 (Amersham Biosciences).
Fluorescence staining of the cells
For the immunofluorescence detection of FN and histidine-tagged proteins in COS-7 cells, the cells were plated to six-well plates containing glass coverslips. After reaching semiconfluency, the cultures were transfected with the indicated expression constructs using Fugene 6 (Roche) according to the manufacturer's instructions. Cells were then maintained in normal serum containing medium for 48 h before fixation.
The transfected cultures were washed with PBS. The cells were then fixed with 3% paraformaldehyde for 15 min. The cells were washed three times with PBS, and nonspecific binding sites were saturated by incubating the cells with 5% BSA in PBS for 30 min. The coverslips were then treated simultaneously with penta-his monoclonal antibody (QIAGEN) and anti-FN rabbit polyclonal antibodies (Sigma-Aldrich), followed by Texas redconjugated antimouse secondary antibody and fluorescein isothiocyanateconjugated antirabbit antibody (Jackson ImmunoResearch Laboratories). After washes, the coverslips were mounted with Vectashield (Vector Laboratories, Inc.).
For actin, vinculin, or paxillin staining of CCL-137 fibroblasts, subconfluent cultures of cells were detached from tissue culture plates with trypsin-EDTA and washed with serum-free medium. The cells were resuspended in serum-free MEM, containing the indicated proteins, and plated onto acid-treated glass coverslips on six-well plate wells (105 cells/well). Coverslips were coated before plating as indicated in the Fibroblast adhesion assays section. After 90 min, the medium was removed, and the cells were fixed with 3% paraformaldehyde in PBS for 20 min. The cells were permeated with 0.1% TX-100 in PBS for 5 min, and nonspecific staining was prevented by incubation with 5% BSA in PBS for 30 min. The cells were finally stained for filamentous actin with tetramethyl rhodamine isothiocyanateconjugated phalloidin (Sigma-Aldrich) in PBS, 0.5% BSA. To detect vinculin, the cells were incubated with anti-vinculin monoclonal antibody (clone hVIN-1; Sigma-Aldrich), and to detect paxillin with anti-paxillin monoclonal antibody (clone 349; BD Biosciences), and subsequently with Texas redconjugated antimouse secondary antibody (Jackson ImmunoResearch Laboratories). After washes, the coverslips were mounted with Vectashield.
Coverslips were observed with an Axioplan 2 microscope (Carl Zeiss MicroImaging, Inc.) using 40x objective. Pictures were taken with AxioCam HR (Carl Zeiss MicroImaging, Inc.) digital camera and AxioVision 3.1 (Carl Zeiss MicroImaging, Inc.) software. Brightness and contrast of the images were adjusted with Corel Photo-Paint (Corel Inc.) and decorated with CorelDRAW (Corel Inc.) software.
Cell spreading and stress fiber quantification
Three independent and randomly chosen pictures were taken at 10x magnification from actin-stained cells. The cell spreading was determined by counting the area of each cell with the aid of Image-Pro software (Media Cybernetics). The average of >100 cells was calculated, and cell spreading on FN was set to one. The cell spreading values of cells on other substrates was then compared with this value. Cells in contact with other cells were excluded from the analysis. Actin stress fibers were quantified from similar pictures by manually counting the percentage of cells forming stress fibers on each substratum.
ELISA
Human plasma FN (Sigma-Aldrich) or native rat tail type I collagen (Upstate Biotechnology) were diluted from stock solutions in acetic acid to PBS to the indicated concentrations. MaxiSorp 96-well plates (Nunc) were then coated with these proteins in PBS at 23°C for 1 h with shaking (as all subsequent steps). Nonspecific protein binding sites were saturated with 3% BSA in PBS (23°C, 1 h). Wells were then washed once with incubation buffer (PBS containing 1 mM CaCl2, 1 mM MgCl2, and 0.5% BSA). This buffer was used in all subsequent washes and incubations. Purified LTBP-2 or fragment L2-N* or L2-V* were diluted and incubated in the wells for 1 h. The wells were next washed twice with the incubation buffer (5 min each). Bound LTBP-2 was detected by incubating the wells with polyclonal affinity-purified antibody ab-L22 for 1 h (Hyytiäinen et al., 1998). LTBP-2 fragments were detected with the penta-his monoclonal antibody. The plates were washed twice (5 min each) and incubated with antirabbit or antimouse horseradish peroxidaseconjugated secondary antibody for 30 min. The wells were finally washed (4 x 10 min) with the incubation buffer, and the bound immune complexes were detected with 1,2-phenylenediamine dihydrochloride (DakoCytomation) according to the manufacturer's instructions. The reaction was terminated with H2SO4, and the color reactions were measured with a spectrophotometer at wavelength 450 nm.
| Acknowledgments |
|---|
This study was supported by the Academy of Finland, Biocentrum Helsinki, Sigrid Juselius Foundation, Novo Nordisk Foundation, The Wihuri Foundation, Helsinki University Hospital Fund, Finnish Cancer Organizations, Oskar Öflund Foundation, Ida Montin Foundation, Biomedicum Foundation, Research and Science Foundation of Farmos, The Finnish Cultural Foundation, and University of Helsinki.
Submitted: 17 September 2003
Accepted: 30 October 2003
| References |
|---|
|
|
|---|
Annes, J.P., J.S. Munger, and D.B. Rifkin. 2003. Making sense of latent TGF-beta activation. J. Cell Sci. 116:217224.
Bax, D.V., S.E. Bernard, A. Lomas, A. Morgan, J. Humphries, C.A. Shuttleworth, M.J. Humphries, and C.M. Kielty. 2003. Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alpha5beta1 and alphavbeta3 integrins. J. Biol. Chem. 278:3460534616.
Chiquet-Ehrismann, R. 1995. Inhibition of cell adhesion by anti-adhesive molecules. Curr. Opin. Cell Biol. 7:715719.[CrossRef][Medline]
Chiquet-Ehrismann, R., P. Kalla, C.A. Pearson, K. Beck, and M. Chiquet. 1988. Tenascin interferes with fibronectin action. Cell. 53:383390.[CrossRef][Medline]
Fischer, D., M. Brown-Ludi, T. Schulthess, and R. Chiquet-Ehrismann. 1997. Concerted action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. J. Cell Sci. 110:15131522.[Abstract]
Flaumenhaft, R., M. Abe, Y. Sato, K. Miyazono, J. Harpel, C.H. Heldin, and D.B. Rifkin. 1993. Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J. Cell Biol. 120:9951002.
Gayraud, B., D.R. Keene, L.Y. Sakai, and F. Ramirez. 2000. New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin-1 mutation in the tight skin mouse. J. Cell Biol. 150:667680.
Gibson, M.A., G. Hatzinikolas, E.C. Davis, E. Baker, G.R. Sutherland, and R.P. Mecham. 1995. Bovine latent transforming growth factor beta 1-binding protein 2: molecular cloning, identification of tissue isoforms, and immunolocalization to elastin-associated microfibrils. Mol. Cell. Biol. 15:69326942.[Abstract]
Gibson, M.A., D.I. Leavesley, and L.K. Ashman. 1999. Microfibril-associated glycoprotein-2 specifically interacts with a range of bovine and human cell types via alphaV beta3 integrin. J. Biol. Chem. 274:1306013065.
Giltay, R., G. Kostka, and R. Timpl. 1997. Sequence and expression of a novel member (LTBP-4) of the family of latent transforming growth factor-beta binding proteins. FEBS Lett. 411:164168.[CrossRef][Medline]
Goicoechea, S., A.W. Orr, M.A. Pallero, P. Eggleton, and J.E. Murphy-Ullrich. 2000. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J. Biol. Chem. 275:3635836368.
Gumbiner, B.M. 1996. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 84:345357.[CrossRef][Medline]
Huang, W., R. Chiquet-Ehrismann, J.V. Moyano, A. Garcia-Pardo, and G. Orend. 2001. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res. 61:85868594.
Hyytiäinen, M., J. Taipale, C.H. Heldin, and J. Keski-Oja. 1998. Recombinant latent transforming growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release. J. Biol. Chem. 273:2066920676.
Isogai, Z., R.N. Ono, S. Ushiro, D.R. Keene, Y. Chen, R. Mazzieri, N.L. Charbonneau, D.P. Reinhardt, D.B. Rifkin, and L.Y. Sakai. 2003. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J. Biol. Chem. 278:27502757.
Kanzaki, T., A. Olofsson, A. Moren, C. Wernstedt, U. Hellman, K. Miyazono, L. Claesson-Welsh, and C.H. Heldin. 1990. TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. Cell. 61:10511061.[CrossRef][Medline]
Kielty, C.M., M. Raghunath, L.D. Siracusa, M.J. Sherratt, R. Peters, C.A. Shuttleworth, and S.A. Jimenez. 1998. The tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J. Cell Biol. 140:11591166.
Lauffenburger, D.A., and A.F. Horwitz. 1996. Cell migration: a physically integrated molecular process. Cell. 84:359369.[CrossRef][Medline]
Miyazono, K., A. Olofsson, P. Colosetti, and C.H. Heldin. 1991. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 10:10911101.[Medline]
Moren, A., A. Olofsson, G. Stenman, P. Sahlin, T. Kanzaki, L. Claesson-Welsh, P. ten Dijke, K. Miyazono, and C.H. Heldin. 1994. Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein. J. Biol. Chem. 269:3246932478.
Mosher, D.F. 1995. Organization of the provisional fibronectin matrix: control by products of blood coagulation. Thromb. Haemost. 74:529533.[Medline]
Murphy-Ullrich, J.E., and M. Höök. 1989. Thrombospondin modulates focal adhesions in endothelial cells. J. Cell Biol. 109:13091319.
Nunes, I., P.E. Gleizes, C.N. Metz, and D.B. Rifkin. 1997. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J. Cell Biol. 136:11511163.
Penttinen, C., J. Saharinen, K. Weikkolainen, M. Hyytiäinen, and J. Keski-Oja. 2002. Secretion of human latent TGF-beta-binding protein-3 (LTBP-3) is dependent on co-expression of TGF-beta. J. Cell Sci. 115:34573468.
Pereira, L., K. Andrikopoulos, J. Tian, S.Y. Lee, D.R. Keene, R. Ono, D.P. Reinhardt, L.Y. Sakai, N.J. Biery, T. Bunton, et al. 1997. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat. Genet. 17:218222.[CrossRef][Medline]
Petit, V., and J.P. Thiery. 2000. Focal adhesions: structure and dynamics. Biol. Cell. 92:477494.[CrossRef][Medline]
Proetzel, G., S.A. Pawlowski, M.V. Wiles, M. Yin, G.P. Boivin, P.N. Howles, J. Ding, M.W. Ferguson, and T. Doetschman. 1995. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat. Genet. 11:409414.[CrossRef][Medline]
Rosenbloom, J., W.R. Abrams, and R. Mecham. 1993. Extracellular matrix 4: the elastic fiber. FASEB J. 7:12081218.[Abstract]
Ruoslahti, E. 1996. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12:697715.[CrossRef][Medline]
Sage, H., R.B. Vernon, S.E. Funk, E.A. Everitt, and J. Angello. 1989. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca2+-dependent binding to the extracellular matrix. J. Cell Biol. 109:341356.
Saharinen, J., and J. Keski-Oja. 2000. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol. Biol. Cell. 11:26912704.
Saharinen, J., J. Taipale, O. Monni, and J. Keski-Oja. 1998. Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J. Biol. Chem. 273:1845918469.
Saharinen, J., M. Hyytiäinen, J. Taipale, and J. Keski-Oja. 1999. Latent transforming growth factor-beta binding proteins (LTBPs) - structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev. 10:99117.[CrossRef][Medline]
Sakamoto, H., T. Broekelmann, D.A. Cheresh, F. Ramirez, J. Rosenbloom, and R.P. Mecham. 1996. Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1. J. Biol. Chem. 271:49164922.
Sanford, L.P., I. Ormsby, A.C. Gittenberger-de Groot, H. Sariola, R. Friedman, G.P. Boivin, E.L. Cardell, and T. Doetschman. 1997. TGF-beta 2 knockout mice have multiple developmental defects that are non-overlapping with other TGF-beta knockout phenotypes. Development. 124:26592670.[Abstract]
Shipley, J.M., R.P. Mecham, E. Maus, J. Bonadio, J. Rosenbloom, R.T. McCarthy, M.L. Baumann, C. Frankfater, F. Segade, and S.D. Shapiro. 2000. Developmental expression of latent transforming growth factor beta binding protein 2 and its requirement early in mouse development. Mol. Cell. Biol. 20:48794887.
Shull, M.M., I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 359:693699.[CrossRef][Medline]
Taipale, J., K. Miyazono, C.H. Heldin, and J. Keski-Oja. 1994. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J. Cell Biol. 124:171181.
Taipale, J., J. Saharinen, K. Hedman, and J. Keski-Oja. 1996. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J. Histochem. Cytochem. 44:875889.[Abstract]
Unsöld, C., M. Hyytiäinen, L. Bruckner-Tuderman, and J. Keski-Oja. 2001. Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J. Cell Sci. 114:187197.[Abstract]
Vaheri, A., and E. Ruoslahti. 1975. Fibroblast surface antigen produced but not retained by virus-transformed human cells. J. Exp. Med. 142:530535.
Vehviläinen, P., M. Hyytiäinen, and J. Keski-Oja. 2003. Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells. J. Biol. Chem. 278:2470524713.
Yin, W., E. Smiley, J. Germiller, R.P. Mecham, J.B. Florer, R.J. Wenstrup, and J. Bonadio. 1995. Isolation of a novel latent transforming growth factor-beta binding protein gene (LTBP-3). J. Biol. Chem. 270:1014710160.
This article has been cited by other articles:
| ||||||||||||||